RxDoctor Payments Data

Pradeep Roy, MD

Psychiatry · Kingwood, TXNPI 1033226352

Payments from drug & device makers

$1,483in general payments, 2019–2025

Across 57 payments — averaging $26.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$334
  • Otsuka America Pharmaceutical, Inc.$232
  • AbbVie$223
  • Sunovion Pharmaceuticals Inc.$115
  • Axsome Therapeutics, Inc.$95
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$88
  • plus $396 from 8 others

What the payments were for

  • Food & beverage$1,483100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,483 in reported general payments places this provider in the 70th percentile of 2,238 psychiatry providers in Texas.

See all psychiatry providers in Texas

Medicare billing

Part B allowed, 2024
$17,093
Medicare patients
63
Services billed
251

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate11$38,555
VyvanseLisdexamfetamine Dimesylate24$9,365
Lisdexamfetamine Dimesylate12$2,974
Aripiprazole14$2,370
Methylphenidate Hcl CdMethylphenidate Hcl18$1,388
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine12$867
Oxcarbazepine15$577
Pregabalin22$544
Olanzapine38$542
Mirtazapine17$379
Quetiapine Fumarate23$254
Lithium Carbonate ErLithium Carbonate15$241
Trazodone Hcl38$195
Escitalopram Oxalate17$192
Benztropine Mesylate15$150

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$334$38,55511 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$59$9,36524 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,238 psychiatry providers in Texas.

Other psychiatry in Kingwood

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →